Adjuvant therapy for endometrial cancer

Area of Science:

• Gynecologic Oncology
• Medical Oncology
• Translational Research

Background:

• Endometrial cancer is a prevalent gynecologic malignancy.
• Early-stage diagnosis often leads to cure with surgery alone.
• Adjuvant therapy decisions rely on recurrence risk, informed by FIGO stage and histology.

Purpose of the Study:

• To review evidence for adjuvant therapy in early and locally advanced uterine cancer.
• To highlight the goal of minimizing toxicity while maintaining high cure rates in early-stage disease.
• To discuss the evolving landscape of combined regimens for locally advanced cases.

Main Methods:

• Literature review of existing evidence.
• Analysis of current treatment guidelines and clinical trial data.
• Exploration of emerging molecular risk stratification strategies.

Main Results:

• Current adjuvant therapy is risk-stratified based on FIGO stage and histology.
• Minimizing toxicity is a key consideration for early-stage endometrial cancer.
• Optimal combined regimens for locally advanced disease are still being defined.
• Molecular profiling shows promise for refining risk prediction.

Conclusions:

• Adjuvant therapy for endometrial cancer requires careful risk assessment.
• Future directions include molecular markers for personalized treatment approaches.
• Ongoing research aims to optimize treatment for all stages of endometrial cancer.